阿斯利康同曼彻斯特大学合作投资1770万美元用于进行肿瘤生物信息学的研究

  近日，阿斯利康公司同曼彻斯特大学达成合作协议，计划在未来5年里投资1150万英镑（1770万美元）在临床试验中利用生物信息学工具来开发针对肿瘤患者的更为个体化的新型疗法。
  需要特别指出的是，这项投资将全力支持曼彻斯特大学的相关研究；据阿斯利康消息显示，这笔资金将会支持一系列计划，比如开发新型的生物信息学系统，用来实时捕捉且整合临床试验安全性、有效性、生物标志物以及药物的分布数据等，同时还会将这些信息以简单容易解释的突变呈现出来。
  这笔投资同时也将帮助研究者在临床研究中开发新型的培训程序，并且开发药物代谢动力学及药效学模型以帮助科学家理解药物在机体中的分布及临床效应。这项合作将使来自临床试验的数据可以被健康专业研究者进行实时地回顾学习，同时也会自动匹配癌症药物的相关信息。
  最后阿斯利康的执行副总裁执行副总裁表示，我们将会在后期对临床试验程式进行修订，同时支持临床研究者们进行更加精确、个体化以及进行快速决策的临床试验疗法的研究。（转化医学网360zhyx.com）
  以上为转化医学网原创翻译整理，转载请注明出处和链接！
转化医学网推荐的新闻阅读：

AstraZeneca to Invest $17.7M in University of Manchester-led Oncology Bioinformatics Effort

AstraZeneca is investing £11.5 million ( $17.7 million) in a five-year partnership with the University of Manchester that will focus on developing and using bioinformatics tools in clinical trials to make more personalized treatment decisions for oncology patients.

Specifically, the funds will support research efforts by investigators at the Centre for Cancer Biomarker Sciences at the Manchester Cancer Research Centre who will collaborate with the clinical trials unit of The Christie NHS Foundation Trust in the UK.

According to AstraZeneca, the funds will support projects such as the development of a new bioinformatics system for capturing and integrating clinical trial safety, efficacy, biomarker and drug distribution data in real time, and then presenting this information in easily interpretable graphs. The funds will also support the development of training programs in clinical research and pharmacokinetic and pharmacodynamic modelling to help investigators understand the distribution and clinical effects of medicines within the body.

The collaboration will allow data from clinical trials to be "reviewed in real time by healthcare professionals and matched with information about cancer medicines," Mene Pangalos, executive vice president of AstraZeneca's Innovative Medicines & Early Development unit, said in a statement. Moreover, "we will be able to modify clinical trial [programs] accordingly and support clinicians to offer more accurate, personalized, and rapid decision-making to patients about their treatment."

The current collaboration adds to existing research partnerships between AstraZeneca and the University of Manchester. Past projects have focused on things like developing treatments for lung cancer, inflammatory research, and developing new drug delivery systems, among others.